

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAWAI USA, INC. AND
SAWAI PHARMACEUTICAL CO., LTD.

Petitioners,

v.

BIOGEN MA, INC.

Patent Owner.

Patent No. 8,399,514

Inter Partes Review IPR2019-00789

**EXPERT DECLARATION OF JACQUELYN BAINBRIDGE, PHARM.D.
IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF
U.S. PATENT NO. 8,399,514**

TABLE OF CONTENTS

	Page
I. QUALIFICATIONS AND BACKGROUND.....	6
A. Education and Experience.....	6
B. Legal Standards and Materials Considered.....	9
C. Retention and Compensation	10
II. PERSON OF ORDINARY SKILL IN THE ART	10
III. BRIEF SUMMARY OF OPINIONS	11
IV. THE '514 PATENT [EX. 1001].....	13
V. BACKGROUND	15
A. Treatment of Psoriasis and Multiple Sclerosis Using Fumaric Acid Esters, Including DMF as a Monotherapy, Was Well-Known Before the Priority Date	15
1. Fumaric acid esters to treat psoriasis.	15
2. DMF as a monotherapy to treat psoriasis.	17
3. Fumaric acid esters to treat multiple sclerosis.....	19
4. DMF as a monotherapy to treat multiple sclerosis.....	21
VI. SCOPE AND CONTENT OF THE PRIOR ART REFERENCES	25
A. Fumaderm Label [Ex. 1020]	25
B. Nugteren-Huying 1990 [Ex. 1029]	26
C. Altmeyer 1994 [Ex. 1030].....	27
D. Mrowietz 1998 [Ex. 1028]	28
E. Nibbering 1993 [Ex. 1024].....	29
F. de Jong 1996 [Ex. 1023]	30
G. Ockenfels 1998 [Ex. 1021].....	31
H. Joshi '999 [Ex. 1009]	32
I. Nieboer 1989 [Ex. 1031].....	33
J. Nieboer 1990 [Ex. 1017].....	35
K. Schimrigk 2004 Abstract [Ex. 1006]	36
L. Brune 2004 Abstract [Ex. 1013]	38

TABLE OF CONTENTS
(continued)

	Page
M. Schimrigk 2004 Poster [Ex. 1012].....	39
N. Kappos 2005 [Ex. 1015].....	42
O. Clinical Trials [Ex. 1010].....	43
P. January 2006 Biogen Press Release [Ex. 1005].....	44
Q. Kappos 2006 [Ex. 1007].....	45
R. May 2006 Biogen Press Release [Ex. 1016].....	46
S. Kappos 2006 Presentation [Ex. 1046].....	47
T. ICH [Ex. 1011].....	49
U. WO '342 [Ex. 1008].....	50
VII. UNPATENTABILITY OF THE '514 PATENT	52
A. Ground 1: All Claims of the '514 Patent Are Obvious Over the January 2006 Biogen Press Release In View of the Schimrigk 2004 Abstract.....	52
1. Independent Claims 1, 11, 15, and 20 Are Obvious Over the January 2006 Biogen Press Release in View of the Schimrigk 2004 Abstract.	52
a. Teachings of the January 2006 Biogen Press Release and the Schimrigk 2004 Abstract.....	54
b. Skilled artisans would have been motivated to pursue, with a reasonable expectation of success, the treatment of MS patients with 480 mg/day of DMF	56
2. Dependent Claims 2-10, 12-14, 16-19 Are Obvious Over the January 2006 Biogen Press Release in View of the Schimrigk 2004 Abstract.	62
B. Ground 2: All Claims of the '514 Patent Are Obvious Over Kappos 2006 In View of The Schimrigk 2004 Abstract.....	67
1. Independent claims 1, 11, 15, and 20 Are Obvious Over Kappos 2006 in View of the Schimrigk 2004 Abstract.	67

TABLE OF CONTENTS
(continued)

	Page
a. Teachings of Kappos 2006 and the Schimrigk 2004 Abstract	67
b. Skilled artisans would have been motivated to pursue, with a reasonable expectation of success, the treatment of MS patients with 480 mg/day of DMF	69
2. Dependent Claims 2-10, 12-14, 16-19 Are Obvious Over Kappos 2006 in View of the Schimrigk 2004 Abstract	79
C. Ground 3: All Claims of the '514 Patent Are Obvious Over Kappos 2006 In View of WO '342	79
1. Independent claims 1, 11, 15, and 20 Are Obvious Over Kappos 2006 in View of WO '342.	79
a. Teachings of Kappos 2006 and WO '342	80
b. Skilled artisans would have been motivated to pursue, with a reasonable expectation of success, the treatment of MS patients with 480 mg/day of DMF	81
2. Dependent Claims 2-10, 12-14, 16-19 Are Obvious Over Kappos 2006 in View of WO '342	82
D. Ground 4: All Claims of the '514 Patent Are Obvious Over Kappos 2006 in View of Clinical Trials, Joshi '999, and ICH	83
1. Independent claims 1, 11, 15, and 20 Are Obvious Over Kappos 2006 in View of Clinical Trials, Joshi '999, and ICH	83
a. Teachings of Kappos 2006, Clinical Trials, Joshi '999, and ICH	83
b. Skilled artisans would have been motivated to pursue, with a reasonable expectation of success, the treatment of MS patients with 480 mg/day of DMF	84

TABLE OF CONTENTS
(continued)

	Page
2. Dependent Claims 2-10, 12-14, 16-19 Are Obvious Over Kappos 2006 in View of Clinical Trials, Joshi '999, and ICH.	86
VIII. THERE ARE NO UNEXPECTED RESULTS.....	87
A. The DEFINE and CONFIRM Studies Do Not Support Unexpected Results	87
1. The Kappos Phase II, DEFINE, and CONFIRM Studies.....	88
2. Skilled Artisans Would Immediately Recognize the Kappos Phase II Study's Discrepancy in the Mean No. of Baseline Gd+ Lesions for the 360 mg/day Treatment Group and Would Normalize the Data.	90
3. The Lead Principle Investigators of the DEFINE and CONFIRM Trials Confirm That the Results for 480 mg/day DMF Are Not Unexpected.....	95
4. The EMA Report Further Confirms that the Results of the DEFINE and CONFIRM Studies for the 480 mg/day Dose of DMF Were Not Unexpected.....	98
B. It is Not Unexpected For Doses Close in Range To Produce Different Pharmacologic Responses.	100
C. Efficacy of the 480 mg/day Dose Would Not Be Unexpected Because Fumaderm® Was Effective at Treating RRMS at 360 mg/day and 720 mg/day Doses of DMF	101
IX. CONCLUSION.....	102

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.